News & Updates
Filter by Specialty:
Lifestyle modification resolves MASLD, improves adiposity in more PLHIV than standard care
Lifestyle modification induced remission of metabolic dysfunction–associated steatotic liver disease (MASLD) in a higher proportion of people living with HIV (PLHIV) than standard care, according to the first randomized controlled trial (RCT) of its kind conducted by researchers from the Chinese University of Hong Kong (CUHK).
Lifestyle modification resolves MASLD, improves adiposity in more PLHIV than standard care
13 Jun 2025
Are statins protective against HCC?
In a study presented at EASL 2025, the use of statins appears to be associated with a reduced risk of hepatocellular carcinoma (HCC) and slower progression of liver fibrosis in individuals with chronic liver disease (CLD).
Are statins protective against HCC?
10 Jun 2025
Atezolizumab-bevacizumab provides optimal balance between survival, QoL benefits in HCC
A network meta-analysis (NMA) reports that the combination regimen comprising atezolizumab and bevacizumab appears to be better than other first-line systemic therapeutic alternatives for advanced hepatocellular carcinoma (HCC) in terms of providing a balance between overall survival (OS) benefit and quality of life (QoL) preservation.
